REGULATORY
Govt to Shed 28 Bil. Yen via Huge Seller Drugs, 20 Bil. Yen via Existing Re-Pricing Rule; Physicians to Win “Plus” Revision
The government has decided to upwardly revise “core” medical reimbursement fees for physicians, dentists, and pharmacists by 0.49% next April on a medical spending basis, while whittling down drug prices and material costs by 1.22% and 0.11%, it was learned…
To read the full story
Related Article
REGULATORY
- US Opens Probe into German Drug Pricing Policies; Could Japan Be Next?
June 24, 2026
- Japan Awards Sakigake Tag to AbbVie’s Bispecific Etentamig
June 24, 2026
- Japan Grants Orphan Status to Vanda, Quoin Drugs, and Lots More
June 24, 2026
- Carvykti Earlier Use Up for Japan Panel Review on June 29
June 23, 2026
- Kampo Industry Calls for Predictable Drug Pricing to Support Stable Supply
June 23, 2026
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…





